Search research articles
Contact Us
Filters
Showing results (401-410 of 738) with videos related to
Page
of 74
Sort By:
Therapeutic Advances in Medical Oncology
|
September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Maria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Cancer Gene Therapy
|
March 23, 2021
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Rodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
Gynecologic Oncology
|
March 9, 2025
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
Jeanne Carter, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology
|
December 22, 2023
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 15, 2014
Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing
Winnie S Liang, Jessica Aldrich, Sara Nasser, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Page
of 74
Search research articles
Search
Showing results (401-410 of 738) with videos related to
Sort By:
Page
of 74
Therapeutic Advances in Medical Oncology
|
September 29, 2022
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Maria-Pilar Barretina-Ginesta, Bradley J Monk, Sileny Han, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Cancer Gene Therapy
|
March 23, 2021
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Rodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 16, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, et al.
Gynecologic Oncology
|
March 9, 2025
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
Jeanne Carter, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology
|
December 22, 2023
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 15, 2014
Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing
Winnie S Liang, Jessica Aldrich, Sara Nasser, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 1, 2024
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, et al.
Page
of 74